|Bid||39.87 x 1100|
|Ask||39.95 x 2200|
|Day's range||39.78 - 40.13|
|52-week range||33.26 - 42.40|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||13.57|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.17 (5.35%)|
|Ex-dividend date||20 May 2021|
|1y target est||47.77|
Will Emma Walmsley’s radical therapy cure GlaxoSmithKline?. The boss’s plan to divide the pharma giant has support – but her own position may hinge on a crucial presentation this week
Emma Walmsley, GlaxoSmithKline chief executive, faces a struggle to win over key shareholders after Elliott Management attracted converts for radical change at the pharma group, according to leading investors. Ahead of GSK’s investor day next week, activist investor Elliott has sown doubt about whether Walmsley should stay to push through the transformation planned for the group after it spun off its consumer health division last year.
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.